- Prof. Enrico Mini, MD, PhD
- Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Website | E-mail
- Dr. Stefania Nobili, PharmD, PhD
Department of Health Sciences, University of Florence, Florence, Italy.
Website | E-mail
Special Issue Introduction
Pharmacogenetics and pharmacogenomics have expanded rapidly over the past years and they are the basis of personalized medicine. The pharmacological treatment of cancer is an ideal field for the application of pharmacogenetics into clinical practice. Testing of patients for genetic markers of efficacy or toxicity of anticancer therapy is increasingly being used as a result of clinical studies based on genotype stratification, availability of approved clinical tests and of an always more robust clinical pharmacogenetic information and guidelines.
This special issue of Cancer Drug Resistance is designed to provide an overview of the role of pharmacogenetics and pharmacogenomics in cancer treatment, including methods of discovery and clinical drug development, available information on drug labels, web resources, and guidelines, with particular regard to specific cancer drug classes. Finally, the integration of somatic pharmacogenomic markers into clinical practice with examples of main cancer types will be also addressed.
KeywordsPharmacogenetics, pharmacogenomics, methodology, clinical trials, anticancer drugs, drug label information, web resources, guidelines
Submission Deadline31 Jan 2019
Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/cdr
Submission Deadline: 31 Jan 2019
Contacts: Elaine Gao, Managing Editor, email@example.com
The following list shows the information of planned papers to this special issue. All the papers submitted to Cancer Drug Resistance will go through a rigorous peer review process. (Please note that the information below is provisional and may be subject to future change.)